Fresenius touts 10-year dialysis mortality reduction

Fresenius (NYSE:FMS) this week released data from an internal annual medical report, touting a 27% reduction in mortality and 22% reduction in hospitalizations amongst its permanent dialysis patients over 10 years.

The Waltham, Mass.-based company said the outcomes are a product of the company’s expansion beyond renal service care into care coordination, as well as continued clinical innovation.

“This group of talented and dedicated clinical leaders is fundamentally changing the way in which we are delivering care for chronically ill individuals. As a result, we are better able to address our patients’ physical and psychological needs while being good stewards of health resources. I am proud that this year’s Annual Medical Report highlights how the commitment and passion of these leaders across our entire organization and their teams are driving our clinical activities toward the highest level of patient outcomes,” chief medical officer Dr. Frank Maddux said in a press release.

Earlier this month, four months after launching a clinical trial accelerator, Fresenius’ renal research arm Frenova disclosed the initial participants.

Fourteen research centers around the U.S. will take part in the F1RST Up accelerator (Frenova Rapid Start Up). Frenova general manager said in prepared remarks that the participants include “some of the most productive clinical research sites in the world of renal research.”

The Waltham, Mass.-based accelerator is designed to propel more studies by taking administrative and contracting burdens out of the clinical trial setup process. Frenova launched F1RST Up in February. Frenova itself was relaunched in March 2014, after having been known as the Clinical Studies Group at FMCNA since its 2001 debut.

The 14 participants: Boise Kidney & Hypertension Institute, Meridian, ID; California Institute of Renal Research, San Diego, CAEastern Nephrology Associates, New Bern, NC; Gamma Medical Research, McAllen, TX; Knoxville Kidney Center, Knoxville, TN; Metro Hypertension & Kidney Center, St. Louis, MO; Nephrology & Hypertension Associates, Tupelo, MS; Nephrology Associates, Columbus, MS; Northeast Clinical Research Center, Bethlehem, PA; Paragon Health d/b/a Nephrology Center, Kalamazoo, MI; Renal Medicine Associates, Albuquerque, NM; South Carolina Nephrology and Hypertension Center, Orangeburg, SC; South Florida Research Institute, Lauderdale Lakes, FL; and Southwest Houston Research, Houston, TX.

In February, Frenova launched the renal research accelerator through an alliance of physician investigators in the nephrology research field.

The post Fresenius touts 10-year dialysis mortality reduction appeared first on MassDevice.

from MassDevice http://ift.tt/28SUJUJ